

[Beractant](#)

Essential medicine status

Section:

[22. Medicines for reproductive health and perinatal care](#) [22.7. Medicines administered to the neonate \[c\]](#)

ATC codes: [R07AA02](#)

EMLc

Indication

Respiratory distress syndrome of newborn ICD11 code: [KB33.0Z](#)

Medicine type

Biological agent

List type

Complementary

Formulations

Respiratory > Suspension: 25 mg per mL for intratracheal instillation (EMLc)

EML status history

First added in 2009 ([TRS 958](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Newborn (< 1 month)

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Biological

Wikipedia

[Beractant](#)

[DrugBank](#)

[Beractant](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended to amend the listing for pulmonary surfactant by replacing "surfactant" with the individual medicine names and dosage form characteristics of the products: Beractant: suspension for intratracheal instillation 25 mg/mL Porcatant alfa: suspension for intratracheal instillation: 80 mg/mL